| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed circulating serum miRNA in patients with cervical cancer using the microRNA array and found that the expression of miR-483-5p, miR-1246, miR-1275, miR‐1290 and miR-100 was significantly different in cervical cancer samples compared with control samples. Using realtime RT-PCR, the expression level of miR‐1290 and miR‐100 was significantly different in the serum samples from cervical cancer patients, but not in those from CIN patients, compared with healthy controls. The expression level of serum miR-1290 increased and that of miR-100 decreased along with the stage of cervical cancer. Also, we found that miR-100 targeted USP 15 which is related to paclitaxel resistance. The expression of miR-100 was significantly increased under hypoxic condition and hypoxia reduced the endogenous USP15 expression in cervical cancer cell lines. Our results provide evidence that regulation of USP15 expression by miR-100 represents a mechanism for paclitaxel resistance in cervical cancer.
|
